
Investments
104Portfolio Exits
13Funds
7Service Providers
1About Sante
Sante is a life sciences venture capital firm that invests exclusively in early-stage companies developing new medical technologies or healthcare delivery models. The company was founded in 2006 and is based in Austin, Texas.

Want to inform investors similar to Sante about your company?
Submit your Analyst Briefing to get in front of investors, customers, and partners on CB Insights’ platform.
Latest Sante News
Jun 28, 2023
SAN FRANCISCO, June 27, 2023-- BeeKeeperAI, Inc., a pioneer in zero-trust, collaboration software for the development and deployment of artificial intelligence (AI), today announced that it has closed $12.1 million in Series A financing. The round was led by Sante Ventures, with participation from the Icahn School of Medicine at Mount Sinai, AIX Ventures, Continuum Health Ventures, TA Group Holdings, and UCSF. The new funding will be used to expand the features of its EscrowAI™ platform as well as broaden commercial operations. “BeeKeeperAI is poised to drive the adoption of zero-trust, confidential computing capabilities by enabling secure collaboration workflows between AI developers and stewards of privacy protected information,” said Michael Blum, MD, CEO and Co-founder of BeeKeeperAI. “With this funding, we will expand the capabilities of EscrowAI and capitalize on the rising demand for zero-trust computing environments that power AI development. Market forces within healthcare and other regulated data industries, powered by the growing demand for AI solutions, including large language models such as ChatGPT, have created the ideal opportunity for BeeKeeperAI to expand our leadership position in the confidential computing space. There has never been a better time to invest in further development of software-as-a-solution (SaaS) that leverages the secure capabilities of confidential computing.” BeeKeeperAI™ is addressing the challenges of data sovereignty, security, privacy, and intellectual property (IP) protection as an increasing number of organizations endeavor to build software applications that unlock the power of AI on privacy protected information. Global cybercrime costs are expected to reach $10.5 trillion by 2025, and no data is more sought after than those from regulated or security industries, including healthcare. Privacy regulations also continue to evolve with stringent requirements and geographical differences, creating the need for zero-trust environments to protect both privacy protected information (PPI) and IP. “Our investment in BeeKeeperAI evolved out of a multi-year search of identifying companies that we believe could significantly accelerate the adoption of AI in healthcare. We believe their proprietary and patented EscrowAI platform solves a major problem for both healthcare data stewards and AI solution providers and can significantly streamline data partnership and collaboration timelines. We are pleased to lead this financing round and support BeeKeeperAI's work in providing zero-trust workflow solutions to enable computing on real-world data,” said Dennis McWilliams, Partner at Sante Ventures. “We look forward to deploying EscrowAI to further secure the privacy of Mount Sinai’s data, and our confidence in EscrowAI is evidenced by our investment in BeeKeeperAI. The deployment will streamline collaborations to positively impact health and well-being for patients and society,” said Erik Lium, PhD, Chief Commercial Innovation Officer at Mount Sinai and President of Mount Sinai Innovation Partners. Powerful Combination of BeeKeeperAI’s SaaS Workflows and Microsoft Azure confidential computing BeeKeeperAI recently announced the general availability of EscrowAI™, its patent-protected, zero-trust collaboration platform. EscrowAI seamlessly integrates Azure confidential computing capabilities, resulting in a push-button ease in deploying a zero-trust workflow to support AI development and deployment. In healthcare, EscrowAI enables HIPAA-compliant research on real-world data without exposing the patient data, thereby dramatically reducing the time required to complete the required approvals and contracting. “As a health tech and longevity focused venture fund, we strive to identify opportunities where AI and data can move us away from a sick care model. With BeeKeeperAI, we are very excited to back founders that understand the global complexity of regulatory (patient privacy) and the dynamic, rapidly evolving nature of medical knowledge. This solution will help to ensure that comprehensive and representative datasets will train the next generation of AI with patient safety, data integrity and clinical efficacy prioritized,” said Ricky Mehra, General Partner at Continuum Health Ventures. As a member of Microsoft for Startups and Microsoft’s Pegasus program, BeeKeeperAI is using Azure services within EscrowAI, which is available to Microsoft customers as an option to purchase directly from Microsoft, simplifying their procurement process. BeeKeeperAI Solves Real-world Data Access Challenges with EscrowAI Platform BeeKeeperAI’s EscrowAI is a patented collaboration workflow solution that sets a new standard in sightless computing. Within the zero-trust workflow the PPI and IP are encrypted: at rest, in transit, and in process. The platform leverages a hardware-based secure enclave environment to bring together the encrypted data and algorithm where they unencrypt in protected memory and execute the computation. Only a predetermined output is allowed out of the enclave. About BeeKeeperAI BeeKeeperAI is the pioneer in confidential, sightless computing within a zero-trust architecture for the development and deployment of AI in healthcare and other privacy protected data. BeeKeeperAI is accelerating the broader availability of AI-powered solutions that will help to redefine the future of healthcare and commerce. For more information, go to www.beekeeperai.com. Contact:
Sante Investments
104 Investments
Sante has made 104 investments. Their latest investment was in Solu Therapeutics as part of their Seed VC on August 8, 2023.

Sante Investments Activity

Date | Round | Company | Amount | New? | Co-Investors | Sources |
---|---|---|---|---|---|---|
8/1/2023 | Seed VC | Solu Therapeutics | $31M | Yes | 1 | |
6/27/2023 | Series A | BeeKeeperAI | $12.1M | Yes | 1 | |
5/4/2023 | Series A | Surgical Safety Technologies | $15M | Yes | 5 | |
3/7/2023 | Seed VC | |||||
2/20/2023 | Series B |
Date | 8/1/2023 | 6/27/2023 | 5/4/2023 | 3/7/2023 | 2/20/2023 |
---|---|---|---|---|---|
Round | Seed VC | Series A | Series A | Seed VC | Series B |
Company | Solu Therapeutics | BeeKeeperAI | Surgical Safety Technologies | ||
Amount | $31M | $12.1M | $15M | ||
New? | Yes | Yes | Yes | ||
Co-Investors | |||||
Sources | 1 | 1 | 5 |
Sante Portfolio Exits
13 Portfolio Exits
Sante has 13 portfolio exits. Their latest portfolio exit was Farapulse on June 24, 2021.
Date | Exit | Companies | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Acquirer | Sources |
---|---|---|---|---|---|
6/24/2021 | Acquired | 16 | |||
9/30/2019 | Reverse Merger | 2 | |||
12/27/2018 | Acquired | 2 | |||
Date | 6/24/2021 | 9/30/2019 | 12/27/2018 | ||
---|---|---|---|---|---|
Exit | Acquired | Reverse Merger | Acquired | ||
Companies | |||||
Valuation | |||||
Acquirer | |||||
Sources | 16 | 2 | 2 |
Sante Fund History
7 Fund Histories
Sante has 7 funds, including Sante Health Ventures IV.
Closing Date | Fund | Fund Type | Status | Amount | Sources |
---|---|---|---|---|---|
9/16/2021 | Sante Health Ventures IV | $260M | 4 | ||
5/29/2019 | Sante Health Ventures III | ||||
4/5/2019 | Gateway VCA 0319 | ||||
4/11/2014 | Sante Health Ventures II | ||||
4/17/2008 | Sante Health Ventures |
Closing Date | 9/16/2021 | 5/29/2019 | 4/5/2019 | 4/11/2014 | 4/17/2008 |
---|---|---|---|---|---|
Fund | Sante Health Ventures IV | Sante Health Ventures III | Gateway VCA 0319 | Sante Health Ventures II | Sante Health Ventures |
Fund Type | |||||
Status | |||||
Amount | $260M | ||||
Sources | 4 |
Sante Team
8 Team Members
Sante has 8 team members, including current Founder, Managing Director, Joseph Cunningham.
Name | Work History | Title | Status |
---|---|---|---|
Joseph Cunningham | Founder, Managing Director | Current | |
Name | Joseph Cunningham | ||||
---|---|---|---|---|---|
Work History | |||||
Title | Founder, Managing Director | ||||
Status | Current |
Compare Sante to Competitors
DBL Partners is a venture capital firm that invests in the cleantech, information technology, sustainable products and services, and healthcare sectors to deliver venture capital returns and enable social, environmental, and economic benefits. It was founded in 2002 and is based in San Francisco, California.

Sciety is an investment syndicate that offers capital market services with a focus on life science. It specializes in investment, finance, market analysis, and more. It is based in Stockholm, Sweden.

Sequoia is a venture capital firm. It seeks to invest in companies operating in the information technology, healthcare, manufacturing, mobile, nanotechnology, financial service, internet, energy, media, and retail sectors. The company was founded in 1972 and is based in Menlo Park, California.
Vertical Ventures is an investment firm. The firm invests in the office, research and development, industrial, and warehouse sectors. It was founded in 2004 and is based in Walnut Creek, California.
Nano3d Biosciences is a company that received a SBIR Phase I grant for a project entitled: In Vitro 3D Lung Tissue Model for Drug Discovery and Toxicity Screening. Their project is the development of a lung tissue model based on a new cell culturing platform utilizing nanoparticle-based reagents and magnetic fields to levitate tissue samples and allow three-dimensional (3D) growth. This method naturally grows tissue at the air-liquid interface and is well suited for co-culturing, which are crucial for an accurate in vitro lung model. The application and market for this product will be drug discovery and toxicity screening. In the early stages of drug development, candidate compounds are screened for efficacy and toxicity in in vitro model systems. Currently, these tests are performed in high-throughput assays using two-dimensional (2D) tissue, but 2D culturing alters cellular responses and often leads to misleading results. Subsequent tests in animal models are costly, ethically contentious, and sometimes inaccurate since model organisms may not faithfully reproduce human responses. The broader impact of this proposal follows from the potential to use the tissue model for improved in vitro efficacy and toxicity assays to reduce the cost of drug development. The reduction of animal testing is also an important goal for ethical reasons. In addition, a lung tissue model that recapitulates natural tissue properties and responses can also find application in toxicity screening of environmental, cosmetic, and industrial factors. The current worldwide expenditure for animal toxicity testing is over $10 billion/yr, and replacement in vitro methods are already over $200 million/yr and growing rapidly. An improved lung model will have significant impact in these areas.

Proclinical provides a unique proposition by delivering on every stage of the life science process to help individuals, teams, and whole organizations. It provides partners with strategic project management, executive search, permanent and contract recruitment, recruitment process outsourcing (RPO), and managed service providers (MSP). Preclinical was founded in 2005 and is based in London, United Kingdom.